Key result
Cangrelor bridging appears safe without additive bleeding or thrombosis during liver transplant after recent coronary stenting.
Why the study?
Perioperative dual antiplatelet therapy management is challenging in complex patients with underlying coagulopathy or recent percutaneous coronary interventions.
Is cangrelor bridge therapy safe and effective in patients with recent percutaneous coronary intervention undergoing liver transplantation?
Case Report (n=2)
Is cangrelor bridge therapy safe and effective in patients with recent percutaneous coronary intervention undergoing liver transplantation?
Cangrelor bridge therapy appears to be a viable and safe option for high-risk patients with recent PCI undergoing liver transplantation.
May support cangrelor bridging in complex liver transplant cases; leaves open need for prospective trials.
BACKGROUND: Management of dual antiplatelet therapy (DAPT) in the perioperative setting is challenging, particularly in complex patient populations, such as those with underlying coagulopathy and/or recent percutaneous coronary interventions. METHODS: In this case series, we describe the perioperative use of cangrelor bridge therapy in two patients undergoing liver transplantation after recent coronary drug-eluting stent placement. OUTCOMES: In both patient cases, cangrelor use as a P2Y12 bridge at a dose of 0.75 μg/kg/min was safe and effective. Both patients were successfully switched back to their oral DAPT regimen post-operatively without additive bleeding or thrombotic complications. CONCLUSION: The use of cangrelor as bridge therapy in high-risk perioperative liver transplant patients appears to be a viable option when DAPT is warranted.
No takes yet. Share an insight, caveat, or question.
Succar et al. (2022) conducted a case report in Liver transplantation after recent percutaneous coronary intervention (n=2). Cangrelor was evaluated on Bleeding or thrombotic complications. Perioperative cangrelor bridge therapy (0.75 μg/kg/min) was safe in 2 liver transplant patients with recent coronary stenting, without additive bleeding or thrombotic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: